Escudier, B. et al.: CheckMate 214 : Efficacy and safety of nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Annals of Oncology 28 (suppl. 5): LBA5, 2017.
Bellmunt, J. et al.: Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376 : 1015-1026, 2017.